Risk Factors and Timing of Default From Treatment for Non-Multidrug-Resistant Tuberculosis in Moldova

International Journal of Tuberculosis and Lung Disease - France
doi 10.5588/ijtld.12.0464
Full Text
Abstract

Available in full text

Date
Authors
Publisher

International Union Against Tuberculosis and Lung Disease

Related search

Risk Factors for Multidrug Resistant Tuberculosis Patients in Amhara National Regional State.

African Health Sciences
Medicine
2015English

Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

Revolutionary New Treatment Regimens for Multidrug-Resistant Tuberculosis

The Lancet Infectious Diseases
Infectious Diseases
2019English

Bedaquiline: New Approach for Treatment of Multidrug-Resistant Tuberculosis

RUHS Journal of Health Science
2019English

Reducing Harm in the Treatment of Multidrug-Resistant Tuberculosis

The Lancet
Medicine
2018English

Hypokalemia Among Patients Receiving Treatment for Multidrug-Resistant Tuberculosis

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2004English

Multidrug Resistant Tuberculosis

British Medical Journal
Medicine
2015English

Multidrug Resistant Tuberculosis: Prevalence and Risk Factors in Districts of Metema and West Armachiho, Northwest Ethiopia

BMC Infectious Diseases
Infectious Diseases
2015English

Hepatotoxicity During Treatment for Multidrug-Resistant Tuberculosis: Occurrence, Management and Outcome

International Journal of Tuberculosis and Lung Disease
MedicinePulmonaryInfectious DiseasesRespiratory Medicine
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy